Common diagnostic errors in dermatology and how dermatopathology helps to avoid them

1. Introduction

Dermatological practice faces a structural problem: the skin has a limited repertoire of clinical patterns (erythema, desquamation, papules, blisters, ulcers), but a very broad spectrum of possible diagnoses. The phenotypic overlap between different diseases facilitates misdiagnosis or delayed diagnosis , with a direct impact on prognosis, costs, and medicolegal risk , especially in skin tumors.

In this context, dermatopathology and coordinated work with a specialized skin biopsy laboratory become a key tool for:

• Reduce diagnostic uncertainty.

• To avoid delays in the diagnosis of high-risk entities, such as melanoma or squamous cell carcinoma.

• Refine therapeutic decisions based on objective histological findings.

The following section reviews some scenarios in which diagnostic error is relatively frequent and analyzes the specific contribution of skin biopsy and the dermatopathologist.

2. Pigmented tumors: from benign nevus to melanoma

2.1 Where the error usually occurs

Clinical and dermatoscopic criteria (ABCDE rule, network patterns, veils, etc.) have improved screening, but do not eliminate the risk of error. Thin, hypopigmented melanomas or those in acral areas may appear clinically benign, while some dysplastic nevi generate false positives.

Studies on delayed diagnosis in melanoma have shown that the lack of early histopathological confirmation or decision-making based on prolonged empirical treatments is associated with more advanced stages at diagnosis and worse survival . [show_150ms_ease-in] » data-testid=»webpage-citation-pill»> journals.lww.com +1

Furthermore, partial biopsies of melanocytic lesions (e.g., shave or punch biopsies of a sector) can underestimate the Breslow thickness or miss invasive areas, leading to errors in staging and surgical planning.

2.2 How dermatopathology helps

• Complete excisional biopsy remains the gold standard when feasible for lesions suspected of being melanoma, due to its better correlation with definitive microstaging.

• The dermatopathology report provides crucial prognostic variables (Breslow thickness, Clark level, ulceration, mitotic index, regression, satellitosis) that guide resection margins, sentinel lymph node biopsy indication, and follow-up plan. [show_150ms_ease-in] » data-testid=»webpage-citation-pill»> MDPI +1

A review by expert dermatopathologists reduces major discrepancies in the diagnosis of melanocytic lesions and improves the quality of the report, with a direct impact on oncological management. [show_150ms_ease-in] » data-testid=»webpage-citation-pill»> sciencedirect.com +1

3. Keratinocytic cascade: actinic keratosis – SCC in situ – invasive SCC

3.1 A «continuum» with oncological potential

In patients with chronic photodamage, actinic keratoses (AK) coexist with areas of squamous cell carcinoma (SCC) in situ and invasive SCC. The clinical presentation can be ambiguous, and these lesions are often mistaken for chronic eczema, psoriasis, or seborrheic keratoses.

Arthroscopic keratoses (AKs) are considered markers of chronic UV radiation exposure and initial injury in most cutaneous squamous cell carcinomas (SCCs) , although only a proportion of them progress to invasive disease. [show_150ms_ease-in] » data-testid=»webpage-citation-pill»> PubMed +1

Cohort studies have estimated an annual risk of progression from actinic keratoses (AK) to invasive squamous cell carcinoma (SCC) ranging from 0.025% to 16% per lesion, with a higher cumulative risk in high-grade AK (Olsen III) and in patients requiring frequent retreatment. [show_150ms_ease-in] » data-testid=»webpage-citation-pill»> sciencedirect.com +1

3.2 Common diagnostic errors

• Systematically treat with cryotherapy or topical treatments without histologically confirming the existence of in situ or invasive SCC, especially in high-risk areas (lip, earlobe, eyelids, nose).

• Minimize painful or rapidly growing hypertrophic keratotic lesions.

3.3 Role of the biopsy and the laboratory

Incisional or excisional biopsy allows:

• Differentiate between in situ and invasive squamous cell carcinoma (SCC) , estimating the degree of differentiation and assessing perineural or vascular invasion. [show_150ms_ease-in] » data-testid=»webpage-citation-pill»> jamanetwork.com +1

• Decide between field treatment (fluorouracil, imiquimod, photodynamic therapy) or surgical approach with wide margins or Mohs surgery in a specialized setting.

A dermatopathology laboratory with experience in oncological skin pathology provides structured reports that facilitate therapeutic decision-making and risk stratification.

4. Erythematous-desquamative inflammatory dermatoses: eczema, psoriasis and beyond

4.1 Clinical and histological overlap

Erythematous-desquamative plaques on the trunk and extremities are a classic cause of confusion between:

• Chronic eczema or contact eczema.

• Vulgar or guttate psoriasis.

• Seborrheic dermatitis, pityriasis rosea, parapsoriasis.

• Drug eruptions and early-stage cutaneous lymphomas.

Several clinicopathological correlation studies in psoriasis and psoriasiform dermatoses show that, although the sensitivity of the clinical impression may be high, the specificity is limited, improving significantly with histological support .

More recently, the existence of a true clinicopathological overlap between psoriasis, eczema, and other psoriasiform dermatoses has been highlighted, even at the immunological level (Th2/Th17 axes, IL-36, β-defensins), reinforcing the need to integrate clinical findings, histology, and, in some cases, biomarkers. [show_150ms_ease-in] » data-testid=»webpage-citation-pill»> PubMed +1

4.2 How dermatopathology reduces errors

• Identify predominant patterns (psoriasiform, spongiotic, lichenoid, etc.) and key signs such as Munro microabscesses, eosinophilic exocytosis, vasculitis, lymphocytic atypia, or epidermotropism, which point toward psoriasis, eczema, toxiderma, or lymphoma, respectively. [show_150ms_ease-in] » data-testid=»webpage-citation-pill»> Zenodo +1

• Suggest alternative diagnoses that might not be on the clinician’s initial list (e.g., early mycosis fungoides in chronic «eczematous» plaques).

In practical terms, a biopsy of a chronic inflammatory dermatosis often changes the therapeutic approach (introduction of phototherapy, systemic or biological agents; discontinuation of the suspected drug) and shortens the trial-and-error process.

5. Blistering diseases and severe skin reactions to drugs

5.1 High-risk scenarios

The spectrum of severe cutaneous drug reactions (SCARs) —including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), DRESS, AGEP— and autoimmune bullous dermatoses (pemphigus, bullous pemphigoid, BSE, etc.) represent another field prone to diagnostic error.

Contemporary series of SJS/TEN underscore its high mortality rate and the need for early diagnosis and appropriate categorization of the clinical presentation to guide intensive support and systemic therapies. [show_150ms_ease-in] » data-testid=»webpage-citation-pill»> link.springer.com +1

5.2 Specific contributions of biopsy and immunopathology

• The combination of conventional biopsy and direct immunofluorescence allows differentiation between intraepidermal and subepidermal cleavage, identification of immunoglobulin and complement deposits, and differentiation of autoimmune blistering from severe toxidermia. [show_150ms_ease-in] » data-testid=»webpage-citation-pill»> pmc.ncbi.nlm.nih.gov +1

• In SCAR, histological examination provides information on the pattern of keratinocytic necrosis and the intensity of the infiltrate, which can help to place the condition within the MS–SSJ–TEN spectrum and rule out alternative diagnoses . [show_150ms_ease-in] » data-testid=»webpage-citation-pill»> actasdermo.org +1

The clinical consequence is clear: an error in classifying these entities can result in undertreatment (e.g., not stopping the triggering drug in time) or overtreatment with immunosuppressants in conditions that do not require it.

6. Good practices to reduce errors: what the dermatopathologist needs from the clinician

For dermatopathology to fulfill its function as a «second line of precision,» the interaction between clinician and laboratory must be systematic and structured:

1. Appropriate selection of biopsy site and type

   • Take active and representative areas, avoiding highly ulcerated or excoriated areas.

   • In melanocytic tumors, prioritize complete excisional biopsy when technically feasible. [show_150ms_ease-in] » data-testid=»webpage-citation-pill»> jamanetwork.com +1

2. Complete and targeted clinical record

   • Time of evolution, symptoms, previous treatments, relevant comorbidities (immunosuppression, oncohematological).

   • Distribution and pattern of lesions, clinical and dermatoscopic photographs when available. The literature highlights that the absence of relevant clinical information can compromise the pathologist’s diagnostic accuracy . [show_150ms_ease-in] » data-testid=»webpage-citation-pill»> www1.racgp.org.au

3. Two-way communication

   • Discuss directly complex or discordant cases between clinical and histological findings.

   • Request dermatopathological reviews or second opinions when the result does not correlate with the patient’s progress. [show_150ms_ease-in] » data-testid=»webpage-citation-pill»> sciencedirect.com +1

In a dermatopathology laboratory in Costa Rica with a focus on clinicopathological correlation such as skinpaths , these steps are integrated into the routine workflow with communication channels always open with clinicians.

7. When should a second dermatopathological review/opinion be considered?

Evidence shows that review by pathologists with specific training in dermatopathology significantly reduces major discrepancies in the diagnosis of melanocytic and non-melanocytic lesions. [show_150ms_ease-in] » data-testid=»webpage-citation-pill»> sciencedirect.com +1

It is reasonable to consider a second opinion in the following scenarios:

• Melanomas or skin tumors with high therapeutic impact (e.g., before performing sentinel lymph node biopsy or mutilating surgery).

• Cases with discrepancy between clinical and histological findings (e.g., “eczematous” plaques that clinically evolve as cutaneous lymphoma).

• Severe skin reactions to drugs or blistering diseases with major prognostic implications.

The availability of a reliable skin biopsy laboratory facilitates these review processes and consolidates diagnostic quality circuits.

8. Conclusion

Diagnostic errors in dermatology are largely a consequence of the clinical overlap between different entities and the undervaluation of biopsy and dermatopathological reports as strategic tools.

Systematically integrating dermatopathology into daily practice—with good sample quality, sufficient clinical information, and fluid communication with the laboratory—allows for:

• To reduce delays and errors in the diagnosis of melanoma and other skin tumors.

• Refine the classification of complex inflammatory dermatoses.

• To better stratify risk in actinic keratoses and squamous cell carcinoma.

• To more safely address severe skin reactions to drugs and bullous dermatoses.

For dermatologists, residents, and other specialists practicing in Costa Rica, working with a dermatopathology laboratory specializing in skin biopsies , such as Skinpaths, not only improves diagnostic accuracy but also translates into safer therapeutic decisions and higher quality care for patients.